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KRAS is themost frequently activated oncogene in human cancer, but it has, so far, shrugged off all attempts
to inhibit its function directly. However, a recent report provides an entirely new approach to blockingmutant
KRAS with small molecules and has the added benefit of sparing the wild-type protein.Closely related protein isoforms encoded
by the RAS family of oncogenes, KRAS,
NRAS, andHRAS, are themost frequently
activated drivers of human cancer (Py-
layeva-Gupta et al., 2011). With some
variations across populations dependent
on smoking rates and ethnicity, RAS
activating mutations are found in about
20% of cancers, with KRAS being the
most frequently mutated, then NRAS,
common in hematological malignancies,
and HRAS a distant third. RAS proteins
are thus exceptionally important players
in cancer and represent an extraordinarily
well-validated drug target. However,
very little progress has been made in
developing drugs that directly inhibit
RAS protein function. A recent report
provides a major advance in this area
and, for the first time, brings into view
the possibility that effective RAS inhibitory
drugs might be on the horizon (Ostrem
et al., 2013).
RAS has long been referred to by
the pharmaceutical industry as ‘‘undrug-
gable,’’ implying that its structure is such
that no direct small molecule inhibitors
can be developed using current tech-
nology. The pharmaceutical industry has
remained wary of RAS, in part due to
the costly failure of farnesyl-transferase
inhibitors, developed in the 1990s to
inhibit the posttranslational isoprenylation
of RAS that is essential for its biological
function. Good farnesyl-transferase inhib-
itors were rapidly obtained, but proved
ineffective in the clinic due to both
alternative processing enzymes and a
lack of specificity for RAS. Targeting
different aspects of RAS posttranslational
processing has been proposed since
then, most recently with the identification
of prenyl-binding protein phosphodies-
terase d inhibitors (Zimmermann et al.,
2013), but it remains hard to see
where the specificity for RAS would beachieved, because more than 60 different
human proteins have been found to be
farnesylated.
RAS sits atop a bifurcating network of
signaling pathways; in the last decade,
most attention has focused on inhibiting
RAS function through the targeting of ki-
nases in the pathways that it controls.
These include protein kinases RAF,
MEK, ERK, and AKT, and the lipid kinase
phosphatidylinositol 3-kinase (PI3K). In-
hibitors of these enzymes are either clini-
cally approved or in advanced clinical
trials. However, their progress in the
clinic has not been smooth. In particular,
given RAS’s ability to activate multiple
pathways, it has been reasoned that
combined targeting of pathways may be
needed to effectively reverse RAS func-
tion, but such drug combinations have
proved to be significantly toxic.
An alternative approach has been to try
to develop drugs that will bind to RAS
directly and inhibit its function. In theory,
it might be possible to prevent RAS from
binding to GTP, the nucleotide required
for RAS to adopt an activated conforma-
tion capable of interacting with down-
stream effector enzymes such as RAF
and PI3K. However, the extraordinarily
high affinity of RAS for GTP makes this
extremely difficult, essentially ruling out
the approach taken successfully with the
ATP binding site of many kinases.
Instead, attention has focused on finding
RAS-binding small molecules that will
block RAS’s interaction with downstream
signaling proteins. High-throughput
screening approaches have been applied
to this problem over many years, for
example, looking for disrupters of RAS-
RAF interaction. This has proved frus-
trating, confirming industry suspicion of
protein-protein interaction inhibitor ap-
proaches, especially when the protein in-
terfaces involved are large and relativelyCancer Cellfeatureless, as is the case for RAS and
its downstream effectors. Although there
have been some promising initial results
(Kato-Stankiewicz et al., 2002), these
have not led to the development of new
drugs.
The search for RAS inhibitors has
escalated recently with the application
of structure-based approaches to the
discovery of direct binding molecules.
A cell permeable synthetic a helix has
been developed that inhibits the interac-
tion of RAS with its upstream activating
guanine nucleotide exchange factor SOS
(Patgiri et al., 2011). However, although
this will prevent wild-type RAS activation
by upstream regulators such as receptor
tyrosine kinases, it would not be expected
to inhibit oncogenic mutant RAS, which
is locked in an activated GTP-bound
form and hence independent of upstream
signal input. In addition, two NMR-
spectroscopy-based small drug fragment
library screens have successfully yielded
direct KRAS binding moieties (Maurer
et al., 2012; Sun et al., 2012). Both studies
identified the same binding pocket on
KRAS adjacent to the GTP-dependent
conformational switch I/II regions. Unfor-
tunately, occupation of this pocket with
the drug fragments blocks KRAS-SOS
interaction, but not interactions with
downstream enzymes such as RAF,
meaning that, by themselves, they are
unlikely to make good inhibitors of mutant
KRAS in cancer. However, these findings
could provide a starting point to design
inhibitors that could reach around to
nearby regions of KRAS that are involved
in effector interaction. A third report
on RAS interaction inhibitors took an
in silico screening approach based on
the structure of a close RAS relative,
MRAS, to find compounds that would
bind GTP-loaded HRAS and block its
interaction with RAF (Shima et al., 2013).25, January 13, 2014 ª2014 Elsevier Inc. 5
Figure 1. The Distribution of Mutations in KRAS Found in Human Cancers
Ostrem et al. (2013) have targeted the cysteine 12 mutant, outlined in red, which accounts for about
12% of total KRAS mutations and is found in about 2% of all human cancers. Common KRAS mutations
involve substitution of reactive amino acid side chains, which may be targetable by similar approaches,
with the exception of valine and alanine at codon 12, marked here by horizontal crosshatches. Data
derived from the COSMIC database (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/).
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junction of the switch I and switch II
regions, but in a distinct orientation to
those described above. However, with
an 20 mM IC50 for the lead compound,
Kobe0065, these inhibitors remain far
from being realistic drugs.
In the new work from Kevan Shokat’s
labaoratory, a quite distinct approach
was taken to finding direct inhibitors of
RAS proteins (Ostrem et al., 2013). They
chose to target a common activated
mutant form of KRAS, bearing a glycine-
to-cysteine substitution at codon 12.
This is the fourth most common KRAS
mutation in human cancer, accounting
for one in eight KRAS mutations overall
(see Figure 1). As a tobacco smoke
induced mutation, its occurrence is
particularly high in lung cancer, where it
is the most common KRAS mutation,
occurring in 40% of KRAS mutant lung
tumors. Overall, 8% of all lung cancers
express this mutant KRAS protein, impli-
cating it in over 100,000 lung cancer
deaths a year worldwide.
The cysteine residue forms a chemi-
cally tractable anchor, which Ostrem
et al. (2013) used to tether compounds,6 Cancer Cell 25, January 13, 2014 ª2014 Elallowing exploration of interactions with
nearby regions of the KRAS protein,
including those involved in effector
enzyme interactions. Initial compounds
formed disulphide interactions with the
cysteine, but this was subsequently
changed to more stable reactive groups,
still yielding covalent interactions and
hence irreversible inhibitors. These inhibi-
tors reduced the viability of KRAS-G12C-
bearing lung cancer cells in culture,
although it is clear that the inhibitors will
require considerable further optimization
before being suitable for use as drugs. A
possible limitation to their effectiveness
could lie in their apparent preference for
the GDP-bound form of KRAS. Although
helpful in locking mutant KRAS into an
inactive state, the compound might not
be able to prevent the initial GTP loading
reaction as newly synthesized KRAS
protein folds. Due to the slow hydrolysis
of GTP on mutant KRAS, this could limit
the degree to which KRAS activity can
be suppressed.
Although the compounds described by
Ostrem et al. (2013) are only an initial step,
they do represent a remarkable advance
in the struggle to target RAS proteinssevier Inc.directly. The selectivity for a common
activating mutant form of the protein
could be advantageous over compounds
that equally target wild-type protein and
may have broader toxicities. Mutant-
selective inhibitors for other oncogene
products such as EGFR have recently
entered clinical trials, and there are
indications of significantly less toxicity
than inhibitors that also target the normal
protein (Walter et al., 2013). Although
the G12C-specific inhibitors are unlikely
to target other mutant versions of KRAS
protein, most mutations found in cancer
involve substitution of reactive amino
acid side chains, which might be target-
able by closely analogous methods.
A particularly attractive mutant in this
regard would beG12D, themost common
KRAS mutation accounting for a third
of all KRAS mutations in cancer (three
times more prevalent than G12C). After
decades languishing in the shadows of
perceived undruggability, it seems that
RAS is finally stepping into the spotlight
as a tractable drug target in human
cancer.
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